GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Yili Chuannig Biotechnology Co Ltd (SZSE:301301) » Definitions » Capital Expenditure

Yili Chuannig Biotechnology Co (SZSE:301301) Capital Expenditure : ¥-393.62 Mil (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Yili Chuannig Biotechnology Co Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Yili Chuannig Biotechnology Co's cash flow for capital expenditures for the three months ended in Mar. 2024 was ¥-55 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-393.62 Mil.

Yili Chuannig Biotechnology Co Capital Expenditure Historical Data

The historical data trend for Yili Chuannig Biotechnology Co's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yili Chuannig Biotechnology Co Capital Expenditure Chart

Yili Chuannig Biotechnology Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capital Expenditure
Get a 7-Day Free Trial -65.44 -89.19 -52.27 -47.20 -345.13

Yili Chuannig Biotechnology Co Quarterly Data
Dec18 Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.57 -87.78 -107.64 -143.15 -55.06

Yili Chuannig Biotechnology Co Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-393.62 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Yili Chuannig Biotechnology Co (SZSE:301301) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Yili Chuannig Biotechnology Co Ltd (SZSE:301301) » Definitions » Capital Expenditure
Comparable Companies
SHSE:688520 SZSE:301207 SZSE:300009 SHSE:688278 SZSE:000403 SHSE:688578 SHSE:688166 SHSE:688639 SHSE:688177 SZSE:300294 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
No. 516, Almatua Village, Yining Park, Horgos Economic Development Zone, Xinjiang, Ili, CHN, 835000
Website
http://www.klcnsw.com
Yili Chuannig Biotechnology Co Ltd adopts the most advanced and mature international biological fermentation, chemical extraction, enzymatic hydrolysis, control and energy saving, and environmental protection technology. The main products of the company include erythromycin thiocyanate, cephalosporin intermediates, penicillin intermediates, and crude ursodeoxycholic acid.

Yili Chuannig Biotechnology Co (SZSE:301301) Headlines

No Headlines